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Abstract
Introduction: Low-grade endometrial stromal sarcoma is very rare and difficult to diagnose in the early stage. A
standard treatment has not been established. In this case report of a patient with long-term survival, we describe
an effective treatment for advanced low-grade endometrial stromal sarcoma.
Case presentation: A 24-year-old Japanese woman who presented with prolonged menstruation was diagnosed
with leiomyoma on the basis of a specimen resected transvaginally. She underwent ten resections in 10 years
without a malignancy diagnosis. During this period, she gave birth. At age 34 years, she visited our hospital,
complaining of lower abdominal pain. A 10cm tumor was detected behind her uterus. The disease was diagnosed
as an advanced malignant ovarian tumor before surgery. A laparotomy was performed, with many remnants left in
the abdominal cavity. The final diagnosis was advanced low-grade endometrial stromal sarcoma. After 12 cycles of
gemcitabine and docetaxel combination chemotherapy, the tumor disappeared completely. A retrospective
pathological review of the specimens resected transvaginally showed that the tumors included low-grade
endometrial stromal sarcoma elements. When the patient was age 42 years, the sarcoma recurred. It was detected
around the right diaphragm and liver. Despite administration of gemcitabine and docetaxel, ascites and pleural
effusion accumulated. Administration of medroxyprogesterone acetate, leuprorelin acetate, and anastrozole
gradually reduced the ascites and pleural effusion. In addition to the three hormone drugs, 18 cycles of paclitaxel
and carboplatin were administered. The patient recovered from her critically ill state and is currently alive with
reduced tumor at age 45 years.
Conclusions: Our patient with low-grade endometrial stromal sarcoma whose disease began in her youth gave
birth and experienced long-term survival with surgery, chemotherapy, and hormone therapy.
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Introduction
Low-grade endometrial stromal sarcoma (LGESS) is very
rare and tends to grow slowly. It develops in the sup-
porting connective tissue (stroma) [1, 2]. Koss and
colleagues stated that endometrial stromal sarcoma con-
stitutes only 0.2% of all uterine cancers and described
long-term survival of ten patients with this disease. The
prognosis of LGESS is better than that of other uterine
sarcomas [3]; however, LGESS is difficult to diagnose in
the early stage or before surgery. A standard treatment is
not established, so women with advanced-stage LGESS
may undergo surgery, hormone treatment, chemotherapy,
or radiation as salvage therapy.
We report a case of a patient with LGESS who has
experienced long-term survival. She gave birth in the
early stage of LGESS, received chemotherapy after sur-
gery in the advanced stage, and was revived by hormone
therapy and additional chemotherapy in the recurrent
stage. We hope this case report plays a role in establish-
ing effective treatment for LGESS.
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Case presentation
Transvaginal tumor resections as benign tumors and
childbirth in the early stage
We report a case of a 24-year-old Japanese woman,
gravida 0, who had no relevant past medical history
or family history when she became ill. She com-
plained of prolonged menstruation and was examined
with Cusco’s speculum. The patient presented with a
uterine cervical tumor and was diagnosed with uter-
ine leiomyoma. She underwent her first transvaginal
resection of the tumor with a myomectomy and
endometrial curettage. The pathological diagnosis was
leiomyoma and endometrium, no malignancy, as a be-
nign tumor. She underwent four additional tumor re-
sections: polypectomy, two myoma resections, and a
submucosal leiomyoma resection via hysteroscopy.
The resections were performed at intervals of 10
months, 9 months, 9 months, and 6 months, respect-
ively. After these resections, she gave birth to a 3396g
boy via cesarean section at age 28 years. During her
pregnancy, she was diagnosed with oligoamnios. The
birth took place at the 39th week of pregnancy. At
age 30 years, the patient developed a sixth tumor (a
fibroid in statu nascendi), which was removed by
exeresis at age 30 years. Four subsequent tumor resec-
tions were performed, at intervals of 23 months, 4
months, 12 months, and 3 months, respectively. When
the seventh tumor was resected by polypectomy at age
32 years, the pathology report revealed for the first time
the high density of the stroma and the necessity of care-
ful follow-up. At the time these ten tumor resections
were performed (five before and five after childbirth),
the tumors were not diagnosed as malignant. The cor-
rect diagnosis was obtained by analysis of advanced-
stage surgical specimens. The discovery of minimal
elements of LGESS by a retrospective study of the trans-
vaginally resected tumors led to a correct diagnosis of
early-stage LGESS.
Treatment in the advanced stage beginning with
abdominal pain
The patient visited our hospital, complaining of lower
abdominal pain at age 34 years and was found to have a
tumor 10cm in diameter behind the uterus (Fig. 1), which
was diagnosed as an advanced malignant ovarian tumor
before surgery. Total abdominal hysterectomy, bilateral
salpingo-oophorectomy, and resection of peritoneal
dissemination were performed. The tumor was classi-
fied as International Federation of Gynecology and Ob-
stetrics 1982 stage VIb for uterine corpus cancer and
Union for International Cancer Control 1990 tumor,
node, metastasis stage pT4NxM1 on the basis of the
finding of tumor spreading in the peritoneal cavity. The
histological result revealed LGESS of the uterine corpus.
A great amount of bulky, disseminated tumor lingered in
the abdominal cavity, particularly on the serosa of the
rectum and descending colon. After the operation,
gemcitabine (800mg/body surface area, Day 1 and 8)
and docetaxel (60mg/body surface area, Day 8)
combination chemotherapy (GD) was started with
informed consent. A subcommittee of our institutional
review board reviewed the case and gave approval to
treat this patient with GD chemotherapy. Six cycles of
GD were administered every 3 weeks, followed by six
cycles every 3 months (age 36 years). After nine cycles
of chemotherapy, the patient developed ileus and under-
went surgery. She had a complete response to chemo-
therapy, and no visible tumor remained in the
abdominal cavity. No recurrent tumor was detected for
the next 4 years, and the patient did not undergo any
treatment during that time.
When the patient reached the age of 40 years, a new
tumor was detected in the pelvic cavity. She underwent
surgery to remove the recurrent tumor. The tumor, 2.5cm
in diameter disseminated on the ileum, was resected.
Numerous small disseminations remained. Five cycles of
GD every 3 weeks were administered after surgery. The
Fig. 1 Pelvic magnetic resonance imaging scans showing advanced low-grade endometrial stromal sarcoma 10cm in diameter behind the uterus
with signal intensities from low to high. a T2-weighted axial slice. b T2-weighted sagittal slice
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sixth cycle of GD was discontinued because the patient’s
neutropenia worsened to a grade 4 adverse event as de-
fined by Common Terminology Criteria for Adverse
Events (CTCAE) version 3, even after granulocyte colony-
stimulating factor was administered. No recurrent tumor
was detected for the next 18 months.
Revival from recurrence between right diaphragm and
liver surface
A small accumulation of fluid was detected in the pouch
of Douglas when the patient was age 42 years. Com-
puted tomography (CT) revealed recurrence of the
tumor in the form of many disseminations in the right
pleura, peritoneum, right diaphragm pleural and peri-
toneal surface, and liver surface (Fig. 2a). Although three
cycles of GD at the initial dose were administered, the
disease progressed and shock was induced by abdominal
cavity bleeding (Fig. 2b). Infusion and blood transfusion
were started with hospitalization to treat bleeding shock.
Medroxyprogesterone acetate (MPA) was administered
at a daily dose of 600mg. Although the bleeding in the
patient’s abdominal cavity stopped, her pleural effusion
and ascites did not decrease. Because the effect of MPA
was not enough, a gonadotropin-releasing hormone
analogue (leuprorelin acetate) at a dose of 3.75mg/body
surface area once every 28 days was administered in
addition to MPA. The increase in both the pleural effu-
sion and ascites accelerated, and thoracic bleeding induced
shock and dyspnea on the 18th day after leuprorelin acet-
ate was first administered (Fig. 2c). The pleural effusion
began to decrease at 1 month after leuprorelin acetate was
first administered. Because the patient’s ascites were not
decreasing, an aromatase inhibitor (anastrozole) 1mg/day
was administered in addition to MPA and leuprorelin
acetate. After beginning treatment with anastrozole, the
patient’s ascites decreased. She was discharged from the
hospital after 116 days.
Three months later, the tumor had enlarged between
the liver and diaphragm and had spread to the right
pleura (Fig. 2d). Paclitaxel at a dose of 170mg/m2 and
carboplatin (area under the curve =4) combination
chemotherapy (TC) was started with MPA, leuprorelin
acetate, and anastrozole. The dose of TC was reduced
because during the time five cycles of GD were adminis-
tered after the recurrent tumor on the ileum was
resected the patient’s neutropenia gradually worsened to
CTCAE grade 4. The tumor size and state were con-
firmed by CT after every three cycles of chemotherapy.
The tumor gradually reduced, and the liver returned to
the normal position. Chemotherapy was stopped after 18
cycles (Fig. 2e). The patient is currently alive and being
treated with MPA, leuprorelin acetate, and anastrozole
(age 45 years at the time of this report).
Pathological review
The first, sixth, and ninth tumors transvaginally resected
in the early stage showed similar histopathological find-
ings. The tumors had a polypoid appearance with vari-
ous degrees of surface erosion (Fig. 3a). The surfaces
were covered by non-atypical columnar epithelium of
endocervical or endometrial type. The stroma was edema-
tous, loosely fibrous, and paucicellular, often containing
capillaries and small vessels recapitulating inflammatory
granulation tissue (Fig. 3b). There were a few foci of mild
stromal hypercellularity, where small, short spindle stro-
mal cells surrounded the blood vessels (Fig. 3c). The sev-
enth, eighth, and tenth transvaginally resected tumors
were clinically diagnosed as endocervical or endometrial
polyps, and they had wide areas of stromal hypercellularity,
which is unusual for conventional endocervical or endo-
metrial polyps (Fig. 3d, e). Although several suspicious
findings were present, it was difficult to diagnose LGESS
on the basis of only transvaginal resection of the tumors.
The surgically resected uterus in the advanced stage
had multiple polypoid excrescences in the lower uterine
segment. Examination of cut sections revealed multiple
nodular lesions in the muscular layer of the uterine cor-
pus and paraovarian connective tissue. The cut surfaces
of these tumors were whitish yellow and had a monot-
onous solid appearance. Multiple peritoneal tumors ran-
ging from 20mm to 60mm in diameter had similar
macroscopic findings.
Histologically, the polypoid endometrial lesions invaded
the muscle layer with pushing margins and multiple
tongue-like projections (Fig. 4a). Prominent intralympha-
tic tumor extensions were noted, especially in the parao-
varian connective tissue (Fig. 4b). The tumor consisted of
a monotonous proliferation of oval to short spindle cells
with indistinct cytoplasm (Fig. 4c). The spindle cells often
surrounded small arterioles in a concentric pattern. Some
cells had abundant clear cytoplasm (Fig. 4d). In some
areas, the stroma was edematous and cellularity was low
(Fig. 4e). Such areas were similar to the pathological find-
ings of the first, sixth, and ninth transvaginal polypectomy
specimens.
Immunohistochemically, the tumor cells of the surgically
resected specimens were diffusely positive for estrogen
receptor, progesterone receptor, and cluster of differenti-
ation 10 (CD10) (Fig. 4f, g, and h). The staining intensity
of progesterone receptor and CD10 was strong, and that
of estrogen receptor was weak to moderate. CD10 was also
positive in the spindle cell of the pre-operative specimens
of the transvaginal resections (Fig. 3f). The series of le-
sions, including those from the ten transvaginal resections
and hysterectomy, were finally diagnosed as LGESS. Focal
stromal hypercellularity surrounding small blood vessels
seen in the first ten resected tumors was retrospectively
considered the characteristic finding of LGESS. The
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Fig. 2 Enhanced computed tomographic scans obtained after tumor recurrence around the right diaphragm and liver surface. a Recurrent tumor
found before administering gemcitabine and docetaxel combination chemotherapy. b Bleeding in the abdominal cavity after administering
gemcitabine and docetaxel combination chemotherapy. c Four weeks after starting medroxyprogesterone acetate and one week after starting
leuprorelin acetate. d Before administering paclitaxel and carboplatin combination chemotherapy and after administering medroxyprogesterone
acetate, leuprorelin acetate, and anastrozole. e After administering 18 cycles of paclitaxel and carboplatin combination chemotherapy and
medroxyprogesterone acetate, leuprorelin acetate, and anastrozole
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recurrent intestinal serosal, peritoneal, and hepatic lesions
showed essentially the same histological findings.
Discussion
LGESS is a rare disease. Several case reports describing
pregnancy after contracting this disease have been pub-
lished [4–6]. In our present report, we describe a case of
childbirth amid repeated tumor resections. Furthermore,
our patient was treated after her condition worsened to the
advanced stage. She underwent surgery, hormone therapy,
and combination chemotherapy. All of these treatment mo-
dalities led to a good response and long-term survival.
The tumors, which had the appearance of uterine myo-
mas or cervical polyps, grew repeatedly during the early
stage over a period of 10 years. The pathological diagnosis
of LGESS could not be made until a hysterectomy was
performed. The usual pathological features of LGESS are
tongue-like myometrial invasions with prominent lymph-
atic involvement and a whorled pattern of oval to short
spindle tumor cells around the arterioles. When these
characteristic features are identified, the pathological diag-
nosis is usually straightforward. However, myometrial
invasion is difficult or almost impossible to identify in
myomectomy or polypectomy specimens. In addition to
the whorled pattern, LGESS has a wide spectrum of less
common histological patterns, including fibroblastic or
myofibroblastic appearance, epithelioid arrangement of
the tumor cells with abundant clear or eosinophilic
cytoplasm, hypocellular myxoid or fibrous change, sex
cord–like elements, glandular differentiation, and pseudo-
papillary pattern [7]. In the specimens of the transvaginal
resections of our patient, significant areas of the lesions
showed a hypocellular granulation tissue-like or fibrous
appearance with less prominent whorled patterns charac-
teristic of LGESS. Those findings are the reason for the
difficulty in pre-operative pathological diagnosis of LGESS
in our patient. Fortunately, the delay of the pathological
diagnosis, with avoidance of hysterectomy, allowed the pa-
tient to give birth.
It was difficult to find effective treatments in a search
of the literature because articles on this topic have been
published only sporadically and report cases only at the
time the tumor had worsened to the advanced stage.
Although surgery, radiation therapy, chemotherapy, and
progestin have been reported as treatments for LGESS,
the effect of these treatments has been limited and inef-
fective in advanced cases. When the next treatment was
investegated after the first abdominal surgery, GD had
been reported as an effective therapy for unresectable leio-
myosarcoma in a phase II trial [8]. GD was considered the
treatment of choice in our patient, although the detailed
histological type in her pathology reports was different
from leiomyosarcoma. Possible use of ifosfamide, doxo-
rubicin, and cisplatin combination therapy (IAP) was also
discussed. There was only one case report of high-grade
endometrial stromal sarcoma [9] that described this
Fig. 3 Histological findings of transvaginal resection. a Polypoid lesion with surface erosion and hemorrhage (lower right). b The stroma was
loosely fibrous with areas of edema. Scattered capillaries and small vessels were seen. c Focal area of hypercellularity. Short spindle stromal cells
surround a small blood vessel. d The seventh transvaginal resection. The stroma is markedly hypercellular. e High-power magnification of image
shown in (d). f Cluster of differentiation 10 immunostaining of the first transvaginal resection
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therapy, which would have produced more severe side ef-
fects than GD. Because GD could be administered in the
outpatient clinic, it was considered that GD would be
better than IAP for our patient from the standpoint of en-
abling her to have a good quality of life. We also discussed
possible use of MPA hormone therapy. Although a few
Fig. 4 Histological findings of surgically resected specimens. a Endometrial lesion of the lower uterine segment. The tumor grew exophytically
and invaded the muscular layer with tongue-like projections. b Prominent intravascular extension in the paraovarian connective tissue. c Oval tumor
cells surround arterioles in a whorl-like pattern. d In some areas, tumor cells have abundant clear cytoplasm and show an epithelioid appearance.
e Foci of hypocellular fibrous areas show similarity to the lesions of the pre-operative transvaginal resections. f, g, and h Immunohistochemical staining
of the surgically resected tumor. f Estrogen receptor. The tumor cells are diffusely positive with weak to moderate signal intensity. g Progesterone
receptor. The tumor cells are diffusely and strongly positive. h Cluster of differentiation 10. The tumor cells are diffusely positive
Maeda et al. Journal of Medical Case Reports  (2015) 9:233 Page 6 of 8
single-case reports about leuprolin acetate [10, 11] or
letrozole [12] had been reported before our patient’s case,
satisfactory descriptions about treatment with these drugs
accumulated later [13, 14]. Because of the severity of our
patient’s disease and the many tumor remnants in her
abdominal cavity, GD was selected rather than MPA as
the treatment of choice. Administration of GD was greatly
effective and led to two complete responses. Until a sar-
coma recurred around her liver and right diaphragm, our
patient survived tumor-free for approximately 8 years after
she first reported abdominal pain and was treated with
surgery followed by GD chemotherapy. During this 8-year
period, progress was made in treatment options for
LGESS, and leuprorelin acetate and anastrozole were re-
ported as effective drugs.
In the second recurrence of our patient’s disease, GD
treatment did not produce a response. It was considered
that the tumor had acquired anti-cancer drug resistance
against GD because of repeated GD administration.
Because MPA as a next treatment was not effective
enough, leuprorelin acetate was administered in addition
to MPA. After administration of leuprorelin acetate, the
patient’s pleural effusion and bleeding accelerated. Leu-
prorelin acetate caused a flare-up of gonadotropin secre-
tion. However, the bleeding stopped after the period of
flare-up of gonadotropin secretion, and the pleural effu-
sion decreased gradually. There was no change in the pa-
tient’s ascites, though, so anastrozole was administered in
addition to MPA and leuprorelin acetate. This treatment
was effective in reducing the ascites, and the patient could
be discharged from the hospital. The three drugs did not
produce side effects, except for bleeding caused by leu-
prorelin acetate.
In the next step, TC was administrated in addition to
hormone therapy. TC was selected because it is a standard
treatment for uterine corpus cancer and is easy to adminis-
ter. TC with MPA, leuprorelin acetate, and anastrozole is
effective for patients with LGESS resistant to GD chemo-
therapy. Although our patient experienced the typical side
effects of chemotherapy, such as alopecia, bone marrow
suppression, and numbness, she underwent 18 cycles of
TC chemotherapy without any more severe side effects
than were expected. A reduced dose would be good for the
patient to continue the repeated chemotherapy. The pa-
tient has survived more than 10 years after the disease
spread throughout her abdominal cavity. However, this
chemotherapy and hormone therapy will cease to be effect-
ive when the patient eventually develops resistance to the
anti-cancer drugs currently used to treat her. A new treat-
ment option is desired for the next recurrence of LGESS.
Conclusions
The diagnosis of LGESS in the early stage is very difficult
only on the basis of transvaginally resected specimens.
Our patient gave birth in the early stage of the disease.
Long-term survival was accomplished via surgery, GD in
the advanced stage, and TC combined with hormone ther-
apy for the GD-resistant tumor in the recurrent stage.
This report should give hope to patients with LGESS. We
hope that combination chemotherapy together with hor-
mone therapy can be established as an effective treatment
for advanced LGESS.
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